Financial Data and Key Metrics Changes - The company achieved record revenue of $1.2 million in Q3 2025, a 32% increase compared to $0.9 million in the same period last year [3][12] - Gross profit for Q3 2025 was $0.8 million, or 66% of revenue, compared to $0.4 million, or 47% in the prior year quarter [13] - The net loss for Q3 2025 was $3.3 million, or $0.40 per share, compared to a net loss of $3.2 million, or $3.63 per share, in Q3 2024 [15] Business Line Data and Key Metrics Changes - The increase in revenue was primarily driven by a rise in Cadmium procedure volumes and the addition of sales from the newly acquired Symmetry SI Joint Fusion System [12] - The company reported over 1,000 Cadmium devices implanted to date, demonstrating strong clinical performance across various indications [6] Market Data and Key Metrics Changes - The demand for both Cadmium and Symmetry products increased throughout Q3 2025 and has continued into Q4 2025 [12] - The company hosted 26 physicians in various workshops to enhance physician education and engagement [10] Company Strategy and Development Direction - The strategic asset acquisition of CyVantage's Symmetry technologies marks a pivotal milestone, transforming the company into a multi-product entity capable of addressing a broader spectrum of sacral pelvic fixation and fusion needs [4] - The company is focused on expanding its product portfolio and leveraging recent regulatory and clinical milestones to support commercial growth [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to drive long-term value for patients, providers, and shareholders, citing strong execution across strategic priorities [18] - The company is actively onboarding sales professionals and expanding its commercial footprint, which is expected to build momentum into Q4 2025 [11] Other Important Information - The company ended Q3 2025 with $3.4 million in cash and no debt, and subsequently raised an additional $2.85 million through pipe financing [10][16] - The FDA granted 510(k) clearance for the Symmetry Plus SI joint fusion system, expanding the company's portfolio and competitive position [8] Q&A Session Summary Question: How much of the $1.2 million in product revenues was from base Cyvanage revenues? - The company had two months of Cyvanage product contribution, with approximately $1.1 million in Cadmium revenue and the rest from early Symmetry activity [20] Question: Will Cadmium grow sequentially from Q3 to Q4 2025? - The company expects Cadmium activity to continue growing, driven by positive data from the Mainsail study and the additional month of CyVantage activity in Q4 [21] Question: How will the Symmetry Plus alpha launch evolve over the next 6 to 12 months? - The alpha launch will start with a small group of physicians for feedback before expanding to a broader audience [23] Question: What are the expectations for G&A expenses moving forward? - G&A expenses in Q3 included some one-time integration costs, but future expenses are expected to be closer to the Q3 figure [24] Question: How is the integration of Cyvanage progressing? - The integration is largely complete, with a focus on launching Symmetry Plus and integrating customer bases [30] Question: What is the strategy for adding commercial sales professionals? - The company is committed to a hybrid commercial structure, with salespeople trained across all products to provide comprehensive solutions to physicians [35]